Contiguous organ resection is safe in patients with retroperitoneal sarcoma: An ACS-NSQIP analysis
- PMID: 21400521
- DOI: 10.1002/jso.21849
Contiguous organ resection is safe in patients with retroperitoneal sarcoma: An ACS-NSQIP analysis
Abstract
Background and objectives: The practice of aggressive contiguous organ resection (COR) of retroperitoneal sarcoma (RPS) is controversial. We examined rates of 30-day morbidity and mortality following resection of RPS utilizing data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database.
Methods: From 2005 to 2007, we identified 156 cases of primary malignant neoplasm of the retroperitoneum. Univariate and multivariate analyses were performed using all pre-operative ACS-NSQIP variables for likelihood of post-operative overall morbidity or severe morbidity (composite endpoint including organ space infection, septic shock, acute renal failure requiring dialysis, reoperation, and death). Insufficient events precluded multivariate analysis of mortality as an independent outcome.
Results: Overall 30-day morbidity, severe morbidity, and mortality were 26% (N = 40), 11.5% (N = 18), and 1.3% (N = 2), respectively. Fifty-eight patients (37%) underwent COR, most commonly kidney. American Society for Anesthesiologists classification predicted overall morbidity (OR 3.23, 95% CI 1.33-7.84), while increasing operative time predicted severe morbidity (OR 1.38 per hour, 95% CI 1.05-1.81). COR was not associated with increased 30-day overall morbidity (OR 1.38, 95% CI 0.49-3.89) or severe morbidity (OR 0.78, 95% CI 0.05-13.18).
Conclusions: Rates of post-operative morbidity and mortality are acceptable following RPS resection, even in the setting of multi-visceral resection. COR should not be viewed as a contraindication to complete RPS resection.
Copyright © 2010 Wiley-Liss, Inc.
Similar articles
-
Morbidity, mortality and temporal trends in the surgical management of retroperitoneal sarcoma: An ACS-NSQIP follow up analysis.J Surg Oncol. 2019 Sep;120(4):753-760. doi: 10.1002/jso.25649. Epub 2019 Jul 29. J Surg Oncol. 2019. PMID: 31355444
-
Effect of resection and outcome in patients with retroperitoneal sarcoma.ANZ J Surg. 2006 Jun;76(6):462-6. doi: 10.1111/j.1445-2197.2006.03753.x. ANZ J Surg. 2006. PMID: 16768769
-
Retroperitoneal sarcoma: 25 years of experience with aggressive surgical treatment at the Institute of Oncology, Ljubljana.J Surg Oncol. 2005 Jul 1;91(1):1-9. doi: 10.1002/jso.20265. J Surg Oncol. 2005. PMID: 15999353
-
[Surgical therapy of retroperitoneal soft tissue sarcomas].Chirurg. 1993 Jul;64(7):527-34. Chirurg. 1993. PMID: 8375202 Review. German. No abstract available.
-
A systematic review of population-based studies examining outcomes in primary retroperitoneal sarcoma surgery.Surg Oncol. 2019 Jun;29:53-63. doi: 10.1016/j.suronc.2019.03.002. Epub 2019 Mar 6. Surg Oncol. 2019. PMID: 31196494
Cited by
-
Postoperative Outcome of Surgery with Pancreatic Resection for Retroperitoneal Soft Tissue Sarcoma: Results of a Retrospective Bicentric Analysis on 50 Consecutive Patients.J Gastrointest Surg. 2021 Sep;25(9):2299-2306. doi: 10.1007/s11605-020-04882-2. Epub 2020 Nov 24. J Gastrointest Surg. 2021. PMID: 33236323
-
Short- and long-term post-nephrectomy outcomes for retroperitoneal liposarcoma from a high-volume sarcoma center: a propensity score matching analysis.Int J Clin Oncol. 2024 Jul;29(7):1035-1043. doi: 10.1007/s10147-024-02530-2. Epub 2024 Apr 23. Int J Clin Oncol. 2024. PMID: 38652434
-
Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.Oncol Lett. 2020 Nov;20(5):190. doi: 10.3892/ol.2020.12052. Epub 2020 Sep 3. Oncol Lett. 2020. PMID: 32952659 Free PMC article.
-
Inferior vena cava resection and reconstruction with a peritoneal patch for a leiomyosarcoma: A case report.Int J Surg Case Rep. 2020;71:37-40. doi: 10.1016/j.ijscr.2020.04.031. Epub 2020 May 8. Int J Surg Case Rep. 2020. PMID: 32438334 Free PMC article.
-
Clinical experience with the treatment of retroperitoneal vascular leiomyosarcoma originating from large veins.BMC Surg. 2021 Aug 15;21(1):326. doi: 10.1186/s12893-021-01322-z. BMC Surg. 2021. PMID: 34392834 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical